GLGuangpu Liu

Guangpu Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guangpu Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Chaofan Zhou

    A liated Hospital Hebei Provincial Tumor Hospital Hebei Cancer Institute Hebei Medical University Fourth

    2 shared publications
  • Cunxian Duan

    Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, PR China

    1 shared publication
  • Dandan Zheng

    Department of Spine Surgery, Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    1 shared publication
  • Dianrui Zhang

    Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, PR China

    1 shared publication
  • Feihu Wang

    Department of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, PR China

    1 shared publication
  • Huixin Zhang

    Department of Obstetrics, The Forth Hospital of Hebei Medical University, Shijiazhuang, China

    1 shared publication

Latest Publications

  • Open Access

    External validation and updating of the Rossi nomogram for predicting cesarean delivery following induction: Is the Bishop score valuable?

    by Guangpu Liu, Jingya Zhang, Chaofan Zhou, Ming Yang, Zhifen Yang, Ling Zhao

    Objective: This study sought to validate the Rossi nomogram in a Chinese population and then to include the Bishop score with the purpose of increasing the accuracy of the nomogram. Materials and Methods: The Rossi predictive model was applied and externally validated in a retrospective cohort from August 2017 and July 2023 in a Chinese tertiary-level medical center. For the revision and updating of the models, the regression coefficients of all the predictors (except race) were re-estimated and then the cervical Bishop score at the time of induction was added. Each model’s performance was measured using the receiver-operating characteristic and calibration plots. Decision curve analysis determined the range of the probability threshold for each prediction model that would be of clinical value. Results: A total of 721 women met the inclusion criteria, of whom 183 (25.4%) underwent a cesarean delivery. The calibration demonstrated the underestimation of the original model, with an area under the curve (AUC) of 0.789 (95% confidence interval [CI] 0.753–0.825, P < 0.001). After recalibrating the original model, the discriminative performance was improved from 0.789 to 0.803. Moreover, the discriminatory power of the updated model was further improved when the Bishop score at the time of induction was added to the recalibrated multivariable model. Indeed, the updated model demonstrated good calibration and discriminatory power, with an AUC of 0.811. The decision curve analysis indicated that all the models (original, recalibrated, and updated) provided higher net benefits of between 0% and 60% of the probability threshold, which indicates the benefits of using the models to make decisions concerning patients who fall within the identified range of the probability threshold. The net benefits of the updated model were higher than those of the original model and the recalibrated model. Conclusion: The nomogram used to predict cesarean delivery following induction developed by Rossi et al. has been validated in a Chinese population in this study. More specifically, adaptation to a Chinese population by excluding ethnicity and including the Bishop score following induction gave rise to better performance. The three models (original, recalibrated, and updated) offer higher net benefits when the probability threshold is between 0% and 60%.

  • Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery

    by Yue Liu, Dianrui Zhang, Cunxian Duan, Lejiao Jia, Pengcheng Xie, Dandan Zheng, Feihu Wang, Guangpu Liu, Leilei Hao, Xueshun Zhang, et al.

    It is reported that the nanosuspension is one of the promising formulations for poorly water-soluble drugs. In order to enhance the in vitro and in vivo behaviours of DDB (bifendate), DDB-NSP (DDB nanosuspensions) have been produced by the precipitation-combined microfluidization method. The optimized DDB-NSP were transformed into dry powders by freeze-drying and then investigated by transmission electron microscopy, laser diffraction and X-ray diffraction (XRD) experiments. Next, the pharmacokinetics and biodistribution of DDB-NSP and DDB-Sol (DDB solution) were carried out. XRD experiments manifested that the crystalline state of DDB was preserved after the size reduction process. An accelerated dissolution velocity and increased saturation solubility could be shown for the DDB-NSP. Compared with DDB-Sol, DDB-NSP exhibited a markedly different pharmacokinetic property with a 17.18-fold increase in AUC0–∞. Meanwhile, the tissue distribution demonstrated that DDB-NSP were mainly uptaken by RES organs particularly by liver. These results supported the fact that nanosuspension, as a promising intravenous drug-delivery system for DDB, could be developed as an alternative to the conventional DDB preparations.